Kiniksa Pharmaceuticals (KNSA) Earnings Date, Estimates & Call Transcripts → top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL) (From Traders Agency) (Ad) Free KNSA Stock Alerts $17.96 +0.10 (+0.56%) (As of 03:21 PM ET) Add Compare Share Share EarningsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Earnings SummaryUpcoming Earnings DateJul. 23EstimatedActual EPS (Apr. 23) -$0.25 Missed By -$0.11 Consensus EPS (Apr. 23) -$0.14 Read Call TranscriptListen to Call Get Kiniksa Pharmaceuticals Earnings AlertsEnter your email address below to receive the latest news and earnings results for KNSA and its competitors with MarketBeat's FREE daily newsletter. Skip Charts & View Estimated and Actual Earnings DataEarnings Per ShareRevenueKNSA Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.KNSA Estimated and Actual Revenue by Quarter Estimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Ad Traders Agencytop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.Click here now for the full details of this stock that’s set to rocket in the AI revolution… Kiniksa Pharmaceuticals Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateQ1 20241($0.13)($0.13)($0.13)Q2 20241($0.06)($0.06)($0.06)Q3 20241($0.02)($0.02)($0.02)Q4 20241$0.01$0.01$0.01FY 20244($0.20)($0.20)($0.20)Q1 20251$0.02$0.02$0.02Q2 20251$0.03$0.03$0.03Q3 20251$0.07$0.07$0.07Q4 20251$0.12$0.12$0.12FY 20254$0.24$0.24$0.24KNSA Earnings Date and InformationKiniksa Pharmaceuticals last released its quarterly earnings data on April 23rd, 2024. The reported ($0.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by $0.11. The firm earned $79.90 million during the quarter, compared to analyst estimates of $76.97 million. Its quarterly revenue was up 65.4% on a year-over-year basis. Kiniksa Pharmaceuticals has generated $0.11 earnings per share over the last year ($0.11 diluted earnings per share) and currently has a price-to-earnings ratio of 163.4. Earnings for Kiniksa Pharmaceuticals are expected to decrease in the coming year, from ($0.06) to ($0.44) per share. Kiniksa Pharmaceuticals has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, July 23rd, 2024 based off prior year's report dates.Read More Kiniksa Pharmaceuticals Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years Time Frame * Start Date * End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript 7/23/2024Estimated)------- 4/23/2024Q1 2024($0.14)($0.25)($0.11)($0.25)$76.97 million$79.90 million 2/28/2024Q4 2023($0.11)$0.04+$0.15($0.27)$72.31 million$83.40 million10/31/2023Q3 2023($0.18)($0.20)($0.02)($0.20)$62.53 million$67.05 million7/25/2023Q2 2023($0.16)($0.02)+$0.14($0.25)$52.33 million$71.47 million5/2/2023Q1 2023($0.18)($0.18)-($0.18)$45.95 million$48.35 million2/28/2023Q4 2022($0.24)$0.06+$0.30$0.06$47.18 million$61.88 million Get the Latest News and Ratings for KNSA and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Kiniksa Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. 11/1/2022Q3 2022$0.38$0.67+$0.29($1.84)$113.00 million$99.14 million8/3/2022Q2 2022($0.43)($0.29)+$0.14($0.29)$27.68 million$26.97 million5/3/2022Q1 2022($0.52)($0.36)+$0.16($0.36)$31.93 million$32.19 million 2/22/2022Q4 2021($0.44)($0.53)($0.09)($0.53)$16.32 million$18.75 million 11/1/2021Q3 2021($0.65)($0.44)+$0.21($0.44)$9.92 million$12.10 million 8/3/2021Q2 2021($0.69)($0.61)+$0.08($0.61)$2.56 million$7.70 million 5/4/2021Q1 2021($0.73)($0.72)+$0.01($0.72)-- Kiniksa Pharmaceuticals Earnings - Frequently Asked Questions When is Kiniksa Pharmaceuticals's earnings date? Kiniksa Pharmaceuticals has not confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, July 23rd, 2024 based off last year's report dates. Learn more on KNSA's earnings history. Did Kiniksa Pharmaceuticals beat their earnings estimates last quarter? In the previous quarter, Kiniksa Pharmaceuticals (NASDAQ:KNSA) missed the analysts' consensus estimate of ($0.14) by $0.11 with a reported earnings per share (EPS) of ($0.25). Learn more on analysts' earnings estimate vs. KNSA's actual earnings. How can I listen to Kiniksa Pharmaceuticals's earnings conference call? The conference call for Kiniksa Pharmaceuticals's latest earnings report can be listened to online. Listen to Conference Call How can I read Kiniksa Pharmaceuticals's conference call transcript? The conference call transcript for Kiniksa Pharmaceuticals's latest earnings report can be read online. Read Transcript How much revenue does Kiniksa Pharmaceuticals generate each year? Kiniksa Pharmaceuticals (NASDAQ:KNSA) has a recorded annual revenue of $270.26 million. How much profit does Kiniksa Pharmaceuticals generate each year? Kiniksa Pharmaceuticals (NASDAQ:KNSA) has a recorded net income of $14.08 million. KNSA has generated $0.11 earnings per share over the last four quarters. What is Kiniksa Pharmaceuticals's price-to-earnings ratio? Kiniksa Pharmaceuticals (NASDAQ:KNSA) has a trailing price-to-earnings ratio of 163.38. What is Kiniksa Pharmaceuticals's EPS forecast for next year? Kiniksa Pharmaceuticals's earnings are expected to decrease from ($0.06) per share to ($0.44) per share in the next year. More Earnings Resources from MarketBeat Related Companies: IRWD Earnings AKRO Earnings PCRX Earnings DCPH Earnings DAWN Earnings ABCL Earnings COLL Earnings OCUL Earnings VRNA Earnings XNCR Earnings Earnings Tools: Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country: U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Australia Earnings Reports Latest Articles: GE Aerospace is Ready for Liftoff After Strong EarningsTaiwan Semiconductor Earnings: AI Dominance and Future OutlookCSX Co.: The Railroad Powering Ahead with an Earnings Beat What's Driving Tesla Lower Ahead of its Earnings?Blackrock vs. State Street: Earnings in a Volatile MarketWhat to Expect From the Q1 Earnings Reporting SeasonLululemon Stock Implodes Post Earnings, Guidance Muted This page (NASDAQ:KNSA) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe A.I. story nobody is telling you (Read ASAP)TradeSmithRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority GoldHe Is Giving Away BitcoinCrypto Swap ProfitsYour Money is Not SafeAmerican Alternative Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kiniksa Pharmaceuticals, Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
